Cargando…

Distinct brain pathologies associated with Alzheimer’s disease biomarker-related phospho-tau 181 and phospho-tau 217 in App knock-in mouse models of amyloid-β amyloidosis

Phospho-tau 217, phospho-tau 231 and phospho-tau 181 in cerebrospinal fluid and plasma are promising biomarkers for the diagnosis of Alzheimer’s disease. All these p-tau proteins are detected in neurofibrillary tangles in brains obtained post-mortem from Alzheimer’s disease patients. However, increa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirota, Yu, Sakakibara, Yasufumi, Ibaraki, Kyoko, Takei, Kimi, Iijima, Koichi M, Sekiya, Michiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683396/ https://www.ncbi.nlm.nih.gov/pubmed/36440096 http://dx.doi.org/10.1093/braincomms/fcac286

Ejemplares similares

Alzheimer’s Disease-Related Phospho-Tau181 Signals Are Localized to Demyelinated Axons of Parvalbumin-Positive GABAergic Interneurons in an App Knock-In Mouse Model of Amyloid-β Pathology
por: Hirota, Yu, et al.
Publicado: (2023)

Widespread Reduced Density of Noradrenergic Locus Coeruleus Axons in the App Knock-In Mouse Model of Amyloid-β Amyloidosis
por: Sakakibara, Yasufumi, et al.
Publicado: (2021)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
por: Marksteiner, Josef, et al.
Publicado: (2022)

Cognitive and emotional alterations in App knock-in mouse models of Aβ amyloidosis
por: Sakakibara, Yasufumi, et al.
Publicado: (2018)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease
por: Tsantzali, Ioanna, et al.
Publicado: (2022)

Drosophila Toll-9 is induced by aging and neurodegeneration to modulate stress signaling and its deficiency exacerbates tau-mediated neurodegeneration
por: Sakakibara, Yasufumi, et al.
Publicado: (2023)

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
por: Wilson, Edward N., et al.
Publicado: (2022)

New Monoterpenoid Indole Alkaloids from Tabernaemontana crassa Inhibit β-Amyloid42 Production and Phospho-Tau (Thr217)
por: Li, Sheng, et al.
Publicado: (2023)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
por: De Meyer, Steffi, et al.
Publicado: (2022)

Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease
por: Sakakibara, Yasufumi, et al.
Publicado: (2019)

Apolipoprotein E decreases tau kinases and phospho-tau levels in primary neurons
por: Hoe, Hyang-Sook, et al.
Publicado: (2006)

Phospho-Tau and Cognitive Decline in Alzheimer's Disease. Commentary: Tau in physiology and pathology
por: DeFelipe, Javier
Publicado: (2016)

Phospho-Tau Bar Code: Analysis of Phosphoisotypes of Tau and Its Application to Tauopathy
por: Kimura, Taeko, et al.
Publicado: (2018)

Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum
por: Meeter, Lieke H.H., et al.
Publicado: (2018)

The study of Tau and phospho Tau protein levels in attention deficit and hyperactivity disorder
por: SARAÇOĞLU, Hatice, et al.
Publicado: (2021)

Phospho-Tau and Chromatin Landscapes in Early and Late Alzheimer’s Disease
por: Gil, Laura, et al.
Publicado: (2021)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

High Levels of β-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse
por: Piccarducci, Rebecca, et al.
Publicado: (2019)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
por: Kac, Przemysław R., et al.
Publicado: (2022)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
por: Simrén, Joel, et al.
Publicado: (2022)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
por: Yu, Lei, et al.
Publicado: (2023)

Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer’s disease and PART
por: Kaufman, Sarah K., et al.
Publicado: (2018)

Soluble phospho-tau from Alzheimer’s disease hippocampus drives microglial degeneration
por: Sanchez-Mejias, Elisabeth, et al.
Publicado: (2016)

Phospho-Tau Changes in the Human CA1 During Alzheimer’s Disease Progression
por: Regalado-Reyes, Mamen, et al.
Publicado: (2019)

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
por: Gonzalez-Ortiz, Fernando, et al.
Publicado: (2023)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
por: Lantero-Rodriguez, Juan, et al.
Publicado: (2023)

Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models
por: Sankaranarayanan, Sethu, et al.
Publicado: (2015)

LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice
por: Lee, Daniel C, et al.
Publicado: (2010)

Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway
por: Inoue, Keiichi, et al.
Publicado: (2012)

The influence of phospho-tau on dendritic spines of cortical pyramidal neurons in patients with Alzheimer’s disease
por: Merino-Serrais, Paula, et al.
Publicado: (2013)

Hippocampal phospho-tau/MAPT neuropathology in the fornix in Alzheimer disease: an immunohistochemical autopsy study
por: Plowey, Edward D., et al.
Publicado: (2016)

Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
por: Hall, Sara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bem7sc2fndm74m1ahfe7cgnhts